Selonterra, founded in the San Francisco Bay Area, is a venture-backed biopharmaceutical company dedicated to transforming therapies for neurodegenerative disorders such as Alzheimer's and Parkinson's disease. The company's core mission is to harness human genetics and gene regulatory networks to develop disease-modifying therapies. Selonterra focuses on identifying genetically linked mechanisms to address these disorders, aiming to create innovative and effective treatments that target unexploited therapeutic areas.

Notable figures affiliated with Selonterra include leading experts in neurogenetics and biopharmaceutical development. The company has garnered significant attention from prominent venture capital firms, reflecting strong investor confidence. Key achievements include the identification of novel therapeutic targets through their unique approach of linking human genetics with gene expression networks. Selonterra's impact lies in its potential to revolutionize the treatment landscape for neurodegenerative diseases, offering hope for millions affected by these debilitating conditions.